Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Investment analysts at B. Riley reduced their FY2018 earnings per share (EPS) estimates for Supernus Pharmaceuticals in a note issued to investors on Thursday, October 4th. B. Riley analyst D. Buck now forecasts that the specialty pharmaceutical company will earn $1.84 per share for the year, down from their previous forecast of $2.05. B. Riley also issued estimates for Supernus Pharmaceuticals’ Q4 2018 earnings at $0.34 EPS.
Several other research firms also recently commented on SUPN. Piper Jaffray Companies set a $47.00 price objective on Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, July 8th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Mizuho initiated coverage on Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective on the stock. Cantor Fitzgerald set a $56.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, June 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $54.67.
SUPN opened at $48.01 on Monday. The stock has a market capitalization of $2.63 billion, a PE ratio of 38.10 and a beta of 0.79. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals has a 12 month low of $33.30 and a 12 month high of $61.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.14. The firm had revenue of $99.54 million during the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SevenBridge Financial Group LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $113,000. Cubist Systematic Strategies LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $203,000. Everence Capital Management Inc. purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $205,000. Cim LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $207,000. Finally, NumerixS Investment Technologies Inc purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $204,000. Hedge funds and other institutional investors own 97.45% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.